Walaa Elnaiem, Amira Yasmine Benmelouka, Ali Mohamed Naguib Elgendy, Mahmoud Shaban Abdelgalil, Muhamad Zakaria Brimo Alsaman, Aly Mogheeth, Mahmoud M. Ali, Shimaa Mohammad Yousof
{"title":"美金刚治疗儿童自闭症谱系障碍的有效性和安全性评价:系统回顾和荟萃分析","authors":"Walaa Elnaiem, Amira Yasmine Benmelouka, Ali Mohamed Naguib Elgendy, Mahmoud Shaban Abdelgalil, Muhamad Zakaria Brimo Alsaman, Aly Mogheeth, Mahmoud M. Ali, Shimaa Mohammad Yousof","doi":"10.1002/hup.2841","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The United States Food and Drug Administration has approved drugs that address only autism-related symptoms rather than the underlying impairments. N-Methyl-D-Aspartate receptor antagonists have recently emerged as a promising treatment option for a variety of neurologic and developmental problems, including autism.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>To review (systematically), for the first time, the medical literature that explores the safety in and efficacy of memantine in autism.</p>\n </section>\n \n <section>\n \n <h3> Methods and procedures</h3>\n \n <p>A comprehensive electronic search for relevant randomized controlled trials was conducted in four databases. Using RevMan software, we extracted and pooled data as a risk ratio (RR) or normalized mean differences in an inverse variance strategy.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>This systematic review and meta-analysis includes five trials. There was no difference in enhancing social responsiveness when compared to placebo, though memantine lowered the likelihood of anxiety (RR = 0.25; 95% Confidence interval: [0.07; 0.87], <i>p</i> = 0.03). However, memantine aggravated impulsive behaviors. Additionally, in another trial that compared memantine added to risperidone versus risperidone added to placebo, memantine was found to be effective and safe.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Memantine showed safety in reducing acute symptoms of anxiety and other symptoms encountered in pediatric patients with autism spectrum disorders. However, memantine does not improve the core symptoms of autism. Nevertheless, further long-term trials are needed to explore its potential efficacy.</p>\n </section>\n </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"37 5","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2022-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis\",\"authors\":\"Walaa Elnaiem, Amira Yasmine Benmelouka, Ali Mohamed Naguib Elgendy, Mahmoud Shaban Abdelgalil, Muhamad Zakaria Brimo Alsaman, Aly Mogheeth, Mahmoud M. Ali, Shimaa Mohammad Yousof\",\"doi\":\"10.1002/hup.2841\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>The United States Food and Drug Administration has approved drugs that address only autism-related symptoms rather than the underlying impairments. N-Methyl-D-Aspartate receptor antagonists have recently emerged as a promising treatment option for a variety of neurologic and developmental problems, including autism.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aims</h3>\\n \\n <p>To review (systematically), for the first time, the medical literature that explores the safety in and efficacy of memantine in autism.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods and procedures</h3>\\n \\n <p>A comprehensive electronic search for relevant randomized controlled trials was conducted in four databases. Using RevMan software, we extracted and pooled data as a risk ratio (RR) or normalized mean differences in an inverse variance strategy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>This systematic review and meta-analysis includes five trials. There was no difference in enhancing social responsiveness when compared to placebo, though memantine lowered the likelihood of anxiety (RR = 0.25; 95% Confidence interval: [0.07; 0.87], <i>p</i> = 0.03). However, memantine aggravated impulsive behaviors. Additionally, in another trial that compared memantine added to risperidone versus risperidone added to placebo, memantine was found to be effective and safe.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Memantine showed safety in reducing acute symptoms of anxiety and other symptoms encountered in pediatric patients with autism spectrum disorders. However, memantine does not improve the core symptoms of autism. Nevertheless, further long-term trials are needed to explore its potential efficacy.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13030,\"journal\":{\"name\":\"Human Psychopharmacology: Clinical and Experimental\",\"volume\":\"37 5\",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2022-03-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Psychopharmacology: Clinical and Experimental\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hup.2841\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.2841","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 3
摘要
美国食品和药物管理局已经批准了仅针对自闭症相关症状而非潜在损害的药物。n -甲基- d -天冬氨酸受体拮抗剂最近作为一种有前途的治疗选择出现在各种神经和发育问题，包括自闭症。目的首次系统地回顾探讨美金刚治疗自闭症的安全性和有效性的医学文献。方法和步骤在4个数据库中对相关随机对照试验进行全面的电子检索。使用RevMan软件，我们提取并汇总数据作为风险比(RR)或在逆方差策略中归一化平均差异。本系统综述和荟萃分析包括5项试验。与安慰剂相比，在增强社会反应方面没有差异，尽管美金刚降低了焦虑的可能性(RR = 0.25;95%置信区间:[0.07;0.87]， p = 0.03)。然而，美金刚加重了冲动行为。此外，在另一项试验中，将美金刚加利培酮与利培酮加安慰剂进行比较，发现美金刚有效且安全。结论美金刚在减轻儿童自闭症谱系障碍患者的急性焦虑等症状方面具有安全性。然而，美金刚并不能改善自闭症的核心症状。然而，需要进一步的长期试验来探索其潜在疗效。
Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis
Background
The United States Food and Drug Administration has approved drugs that address only autism-related symptoms rather than the underlying impairments. N-Methyl-D-Aspartate receptor antagonists have recently emerged as a promising treatment option for a variety of neurologic and developmental problems, including autism.
Aims
To review (systematically), for the first time, the medical literature that explores the safety in and efficacy of memantine in autism.
Methods and procedures
A comprehensive electronic search for relevant randomized controlled trials was conducted in four databases. Using RevMan software, we extracted and pooled data as a risk ratio (RR) or normalized mean differences in an inverse variance strategy.
Results
This systematic review and meta-analysis includes five trials. There was no difference in enhancing social responsiveness when compared to placebo, though memantine lowered the likelihood of anxiety (RR = 0.25; 95% Confidence interval: [0.07; 0.87], p = 0.03). However, memantine aggravated impulsive behaviors. Additionally, in another trial that compared memantine added to risperidone versus risperidone added to placebo, memantine was found to be effective and safe.
Conclusion
Memantine showed safety in reducing acute symptoms of anxiety and other symptoms encountered in pediatric patients with autism spectrum disorders. However, memantine does not improve the core symptoms of autism. Nevertheless, further long-term trials are needed to explore its potential efficacy.
期刊介绍：
Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal:
-All aspects of clinical psychopharmacology-
Efficacy and safety studies of novel and standard psychotropic drugs-
Studies of the adverse effects of psychotropic drugs-
Effects of psychotropic drugs on normal physiological processes-
Geriatric and paediatric psychopharmacology-
Ethical and psychosocial aspects of drug use and misuse-
Psychopharmacological aspects of sleep and chronobiology-
Neuroimaging and psychoactive drugs-
Phytopharmacology and psychoactive substances-
Drug treatment of neurological disorders-
Mechanisms of action of psychotropic drugs-
Ethnopsychopharmacology-
Pharmacogenetic aspects of mental illness and drug response-
Psychometrics: psychopharmacological methods and experimental design
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
